JP2022527190A - 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物 - Google Patents

肝疾患の治療で使用するためのｇｈｒｈまたはその類似物 Download PDF

Info

Publication number
JP2022527190A
JP2022527190A JP2021557925A JP2021557925A JP2022527190A JP 2022527190 A JP2022527190 A JP 2022527190A JP 2021557925 A JP2021557925 A JP 2021557925A JP 2021557925 A JP2021557925 A JP 2021557925A JP 2022527190 A JP2022527190 A JP 2022527190A
Authority
JP
Japan
Prior art keywords
ghrh
hexenoyl
pharmaceutically acceptable
trans
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527190A5 (https=
Inventor
スティーヴン・ケー・グリンスプーン
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2022527190A publication Critical patent/JP2022527190A/ja
Publication of JP2022527190A5 publication Critical patent/JP2022527190A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021557925A 2019-03-29 2020-03-27 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物 Pending JP2022527190A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962826284P 2019-03-29 2019-03-29
US62/826,284 2019-03-29
US201962861187P 2019-06-13 2019-06-13
US62/861,187 2019-06-13
PCT/US2020/025180 WO2020205498A1 (en) 2019-03-29 2020-03-27 Ghrh or analogues thereof for use in treatment of hepatic disease

Publications (2)

Publication Number Publication Date
JP2022527190A true JP2022527190A (ja) 2022-05-31
JP2022527190A5 JP2022527190A5 (https=) 2023-04-05

Family

ID=72607731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557925A Pending JP2022527190A (ja) 2019-03-29 2020-03-27 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物

Country Status (10)

Country Link
US (4) US10799562B1 (https=)
EP (1) EP3947426A4 (https=)
JP (1) JP2022527190A (https=)
KR (1) KR20210145226A (https=)
CN (1) CN113646327A (https=)
AU (1) AU2020253828A1 (https=)
CA (1) CA3133319A1 (https=)
IL (1) IL286703A (https=)
SG (1) SG11202110469PA (https=)
WO (1) WO2020205498A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110469PA (en) 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease
CN115884783A (zh) * 2020-07-05 2023-03-31 瑟瑞技术公司 Ghrh类似物的低剂量药物组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678083A (zh) * 2007-04-04 2010-03-24 瑟瑞技术公司 Ghrh分子的药物制剂
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20150174207A1 (en) * 2013-12-24 2015-06-25 University Of Miami Methods for treating cancer with ghrh agonists
US20170105996A1 (en) * 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
WO2017181277A1 (en) * 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
KR20200121308A (ko) * 2018-02-14 2020-10-23 루모스 파마, 인크. 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물
SG11202110469PA (en) * 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease
WO2022093757A1 (en) * 2020-10-30 2022-05-05 The General Hospital Corporation Kits, reagents and methods for the assessment of liver diseases
US20220152012A1 (en) * 2020-11-16 2022-05-19 The Regents Of The University Of California Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GROWTH HORMONE & IGF RESEARCH, vol. 37, JPN6024011713, 2017, pages 1 - 6, ISSN: 0005452178 *
GUT, vol. 66, no. 1, JPN6024011714, 2017, pages 180 - 190, ISSN: 0005452179 *
JAMA, AUTHOR MANUSCRIPT, JPN6024011715, 1 July 2015 (2015-07-01), pages 1 - 18, ISSN: 0005452180 *

Also Published As

Publication number Publication date
US10946073B2 (en) 2021-03-16
US11738066B2 (en) 2023-08-29
US10799562B1 (en) 2020-10-13
EP3947426A4 (en) 2023-01-04
WO2020205498A1 (en) 2020-10-08
EP3947426A1 (en) 2022-02-09
US20240091316A1 (en) 2024-03-21
KR20210145226A (ko) 2021-12-01
US20200405816A1 (en) 2020-12-31
CN113646327A (zh) 2021-11-12
AU2020253828A1 (en) 2021-10-28
US12233107B2 (en) 2025-02-25
SG11202110469PA (en) 2021-10-28
IL286703A (en) 2021-10-31
US20210177943A1 (en) 2021-06-17
US20200306345A1 (en) 2020-10-01
CA3133319A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
WO2002024214A2 (en) Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders
KR20250151568A (ko) 퍼투주맙 + 트라스투주맙 고정 용량 조합
Zheng et al. Role of mast cells in early and delayed radiation injury in rat intestine
US12233107B2 (en) GHRH or analogues thereof for use in treatment of hepatic disease
US10975146B2 (en) Interleukin-1 inhibition for combination treatment of pancreatic cancer
JP2017025086A (ja) 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
Bruno et al. Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial
JP2022527412A (ja) がんの治療にセネカバレーウイルス（ｓｖｖ）を使用する組成物および方法
CN120676946A (zh) Debio-0123与替莫唑胺和放射治疗组合用于治疗胶质瘤
JP2025509508A (ja) アムセネストラントを用いた乳癌の治療
US20230226154A1 (en) Compositions and methods for treating cancer
CN118742305A (zh) 用于治疗疾病的口服奥曲肽
CN103327978A (zh) 用表皮生长因子受体抑制剂治疗肝纤维化和前肝硬化的方法
EP4653014A1 (en) Biliary tract cancer treatment agent
WO2019182861A1 (en) Therapy for hepatocellular carcinoma
EP4643862A1 (en) Pharmaceutical composition and use thereof
Kim et al. Pancreatic enzyme replacement therapy for prevention of postpancreatectomy hepatic steatosis after pancreatoduodenectomy: a post hoc analysis of a randomized placebo-controlled trial
US20150023920A1 (en) Novel compositions and methods for preventing or treating cancer metastasis
HK40130961A (en) Pharmaceutical composition and use thereof
CN117018197A (zh) 促进dock11表达的试剂作为治疗神经病理性疼痛药物的应用
EP4658785A1 (en) Methods for reducing the risk of major adverse cardiovascular events in primary prevention subjects
CN120078888A (zh) 一种治疗肺癌的药物组合物及其应用
CN115315268A (zh) 用于治疗非酒精性脂肪性肝炎(nash)的组合物和方法
JP2022519328A (ja) 癌の治療
NZ710730A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241105